Viewing Study NCT06217757


Ignite Creation Date: 2025-12-24 @ 6:37 PM
Ignite Modification Date: 2025-12-28 @ 8:54 PM
Study NCT ID: NCT06217757
Status: RECRUITING
Last Update Posted: 2024-05-13
First Post: 2024-01-11
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC
Sponsor: Sichuan University
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module